Table 4.
Treatment related adverse events* during WBRT.
| AEs recorded during treatment (n = 21) | Any grade, n (%) | Grade 3–4a, n (%) |
|---|---|---|
| AEs attributed to WBRT | ||
| Radiation dermatitis | 15 (71%) | |
| Alopecia (any grade) | 18 (86%) | |
| Headache | 7 (33%) | |
| Nausea (during WBRT) | 3 (14%) | 1 (5%) |
| Vomiting (during WBRT) | 2 (10%) | |
| Cognitive changes | 2 (10%) | 1 (5%) |
| AEs attributed to WBRT and/or anti-PD1, possibly synergistic | ||
| Stevens–Johnson syndrome | 1 (5%) | 1 (5%) |
| Vitiligo in WBRT field only | 1 (5%) | |
| AEs attributed to anti-PD-1 antibody | ||
| Diarrhea | 3 (14%) | |
| Pruritus | 4 (19%) | |
| Rash | 5 (24%) | 2 (10%) |
| Hepatotoxicity | 2 (10%) | |
| Endocrinopathy | 3 (14%) | |
| Arthralgia | 1 (5%) |
*
All recorded adverse events occurring due to radiotherapy treatment or affecting the radiotherapy field are shown. All patients given WBRT and anti-PD-1 antibody prior to October 31, 2015 were included in assessment of toxicity.
Abbreviations: SRS, stereotactic radiosurgery.
a
There was one grade 5 event, the investigator assessed as possibly treatment related.